{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T08:54:14Z","timestamp":1789203254756,"version":"build-2803163510"},"reference-count":22,"publisher":"The Journal of Rheumatology","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2011,7]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To evaluate the frequency of malignancies in Italian patients with systemic sclerosis (SSc) and anti-RNA polymerase III (RNAP III), antitopoisomerase I (topo I), or anticentromere antibodies (ACA); and to characterize the temporal relationship between the 2 diseases, in order to confirm data suggesting a close temporal relationship between the onset of SSc and malignancy in American patients with anti-RNAP III antibodies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>From a cohort of 466 consecutive SSc patients, 360 Italians with isolated positivity for anti-RNAP III (n = 16), anti-topo I (n = 101), or ACA (n = 243) were identified. Malignancy cases were divided according to their relationship with SSc onset into 3 categories: preceding, synchronous with, or metachronous to the onset of SSc (diagnosed more than 6 months before; 6 months before to 12 months after; and more than 12 months after onset of SSc, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Malignancies were more frequent in the anti-RNAP III group (7\/16 patients), than in the anti-topo I (11\/101) and ACA groups (21\/243) (p &lt; 0.001). This difference was accounted for by the number of patients with cancer synchronous to the onset of SSc (3\/16 in the anti-RNAP III group vs 0\/101 in the anti-topo I and 1\/243 in the ACA group; p &lt; 0.001), whereas neither the number of malignancies preceding nor those metachronous to the onset of SSc was significantly different between the groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>In a cohort of Italian patients with SSc we observed a significant association between malignancies synchronous to SSc onset and positivity for anti-RNAP III antibodies, similar to that described in American patients with SSc.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.101144","type":"journal-article","created":{"date-parts":[[2011,4,2]],"date-time":"2011-04-02T03:52:41Z","timestamp":1301716361000},"page":"1329-1334","source":"Crossref","is-referenced-by-count":96,"title":["Malignancies in Italian Patients with Systemic Sclerosis Positive for Anti-RNA Polymerase III Antibodies"],"prefix":"10.3899","volume":"38","author":[{"given":"PAOLO","family":"AIRO\u2019","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANGELA","family":"CERIBELLI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ILARIA","family":"CAVAZZANA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MARA","family":"TARABORELLI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"STEFANIA","family":"ZINGARELLI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FRANCO","family":"FRANCESCHINI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2011,4,1]]},"reference":[{"key":"2018112909263844000_38.7.1329.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2007.12.001"},{"key":"2018112909263844000_38.7.1329.2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-119-10-199311150-00007"},{"key":"2018112909263844000_38.7.1329.3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.1.15"},{"key":"2018112909263844000_38.7.1329.4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090600"},{"key":"2018112909263844000_38.7.1329.5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100124"},{"key":"2018112909263844000_38.7.1329.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2009.02.002"},{"key":"2018112909263844000_38.7.1329.7","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080806"},{"key":"2018112909263844000_38.7.1329.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.27549"},{"key":"2018112909263844000_38.7.1329.9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/34.6.104"},{"key":"2018112909263844000_38.7.1329.10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090677"},{"key":"2018112909263844000_38.7.1329.11","first-page":"373","article-title":"Validation of a new immunoenzymatic method to detect antibodies to RNA polymerase III in systemic sclerosis","volume":"25","author":"Codullo","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"2018112909263844000_38.7.1329.12","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J Rheumatol"},{"key":"2018112909263844000_38.7.1329.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230510"},{"key":"2018112909263844000_38.7.1329.14","unstructured":"Valentini G Medsger TA Jr Silman AJ Bombardieri S . The assessment of the patient with systemic sclerosis. Clin Exp Rheumatol 2003;Suppl 29:S1\u2013S56."},{"key":"2018112909263844000_38.7.1329.15","first-page":"2159","article-title":"A disease severity scale for systemic sclerosis: development and testing","volume":"26","author":"Medsger","year":"1999","journal-title":"J Rheumatol"},{"key":"2018112909263844000_38.7.1329.16","first-page":"80","article-title":"The clinical relevance of autoantibodies in scleroderma","volume":"5","author":"Ho","year":"2003","journal-title":"Arthtritis Res Ther"},{"key":"2018112909263844000_38.7.1329.17","doi-asserted-by":"publisher","DOI":"10.1186\/ar2965"},{"key":"2018112909263844000_38.7.1329.18","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950901)76:5<910::AID-CNCR2820760528>3.0.CO;2-T"},{"key":"2018112909263844000_38.7.1329.19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09861.x"},{"key":"2018112909263844000_38.7.1329.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03540-6"},{"key":"2018112909263844000_38.7.1329.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.21646"},{"key":"2018112909263844000_38.7.1329.22","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.1780390423","article-title":"Enhancement of anti-DNA topoisomerase I autoantibody response after lung cancer in patients with systemic sclerosis. A report of two cases","volume":"39","author":"Kuwana","year":"1996","journal-title":"Arthritis Rheum"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.101144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T18:04:01Z","timestamp":1543514641000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.101144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,1]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2011,7,1]]},"published-print":{"date-parts":[[2011,7]]}},"alternative-id":["10.3899\/jrheum.101144"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.101144","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,1]]}}}